Biocon Biologics Now 100% Biocon-Owned After Landmark Deal

Biocon Ltd will acquire the remaining 23.3% stake in Biocon Biologics for USD 1.17 billion, making it a wholly-owned subsidiary. The deal, funded via cash and share swaps, values BBL at USD 5.5 billion. Analysts see long-term growth potential, with S&P Global placing Biocon Biologics on a positive credit watch.

Show more

Stay Ahead – Explore Now! QMS Medical Raises Stake In Saarathi Healthcare To 75 Percent With ₹140 Million Acquisition